In the early twenty-first century, societies around the world are facing the paradoxal epidemic development of PCa as a non-communicable disease. PCa is the most frequently diagnosed cancer for men in several countries such as the USA. Permanently improving diagnostics and treatments in the PCa management causes an impressive divergence between, on one hand, permanently increasing numbers of diagnosed PCa cases and, on the other hand, stable or even slightly decreasing mortality rates. Still, aspects listed below are waiting for innovate solutions in the context of predictive approaches, targeted prevention and personalisation of medical care (PPPM / 3PM).A.PCa belongs to the cancer types with the highest incidence worldwide. Corresponding economic burden is enormous. Moreover, the costs of treating PCa are currently increasing more quickly than those of any other cancer. Implementing individualised patient profiles and adapted treatment algorithms would make currently too heterogeneous landscape of PCa treatment costs more transparent providing clear "road map" for the cost saving.B.PCa is a systemic multi-factorial disease. Consequently, predictive diagnostics by liquid biopsy analysis is instrumental for the disease prediction, targeted prevention and curative treatments at early stages.C.The incidence of metastasising PCa is rapidly increasing particularly in younger populations. Exemplified by trends observed in the USA, prognosis is that the annual burden will increase by over 40% in 2025. To this end, one of the evident deficits is the reactive character of medical services currently provided to populations. Innovative screening programmes might be useful to identify persons in suboptimal health conditions before the clinical onset of metastasising PCa. Strong predisposition to systemic hypoxic conditions and ischemic lesions (e.g. characteristic for individuals with Flammer syndrome phenotype) and low-grade inflammation might be indicative for specific phenotyping and genotyping in metastasising PCa screening and disease management. Predictive liquid biopsy tests for CTC enumeration and their molecular characterisation are considered to be useful for secondary prevention of metastatic disease in PCa patients.D.Particular rapidly increasing PCa incidence rates are characteristic for adolescents and young adults aged 15-40 years. Patients with early onset prostate cancer pose unique challenges; multi-factorial risks for these trends are proposed. Consequently, multi-level diagnostics including phenotyping and multi-omics are considered to be the most appropriate tool for the risk assessment, prediction and prognosis. Accumulating evidence suggests that early onset prostate cancer is a distinct phenotype from both aetiological and clinical perspectives deserving particular attention from view point of 3P medical approaches.

Center of Molecular Biotechnology Rheinische Friedrich Wilhelms Universität Bonn Bonn Germany

Department of Immunochemistry Diagnostics University Hospital and Faculty of Medicine Pilsen Czech Republic

Department of Radiation Oncology University Hospital Bonn Rheinische Friedrich Wilhelms Universität Bonn Bonn Germany

European Medical Association Brussels Belgium

Predictive Preventive and Personalised Medicine Department of Radiation Oncology University Hospital Bonn Rheinische Friedrich Wilhelms Universität Bonn Sigmund Freud Str 25 53105 Bonn Germany

Zobrazit více v PubMed

Golubnitschaja O, Raj Dahal A. Prostate cancer: decreasing age, increasing incidence of metastatic disease and high CTC potential prompts the paradigm shift from reactive to predictive, preventive and personalised medicine in disease management. EPMA J. 2020. 10.1007/s13167-020-00206-1.

GLOBOCAN 2018, https://www.uicc.org/news/new-global-cancer-data-globocan-2018, Accessed on April 27th 2020.

Ballar Kirmizibayrak P, Erbaykent-Tepedelen B, Gozen O, Erzurumlu Y. Divergent Modulation of Proteostasis in Prostate Cancer. Adv Exp Med Biol. 2020. 10.1007/978-3-030-38266-7_5. PubMed

Ihle CL, Owens P. Integrating the immune microenvironment of prostate cancer induced bone disease. Mol Carcinog. 2020. 10.1002/mc.23192. PubMed

Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019. 10.14740/wjon1191. PubMed PMC

Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33:272–277. doi: 10.1200/JCO.2014.55.1192. PubMed DOI

Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004. 10.1158/1078-0432.CCR-04-0378. PubMed

Hench IB, Cathomas R, Costa L, Fischer N, Gillessen S, Hench J, et al. Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). Cancers (Basel). 2019;11. 10.3390/cancers11081099. PubMed PMC

Buscail E, Chiche L, Laurent C, Vendrely V, Denost Q, Denis J, et al. Tumor-proximal liquid biopsy to improve diagnostic and prognostic performances of circulating tumor cells. Mol Oncol. 2019. 10.1002/1878-0261.12534. PubMed PMC

Stefanovic S, Deutsch TM, Wirtz R, Hartkopf A, Sinn P, Schuetz F, et al. Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells. Cancers (Basel). 2019. 10.3390/cancers11030342. PubMed PMC

Yang DX, Makarov DV, Gross CP, Yu JB. Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening. Cancer Control. 2020. 10.1177/1073274820902267. PubMed PMC

Bleyer A, Spreafico F, Barr R. Prostate cancer in young men: An emerging young adult and older adolescent challenge. Cancer. 2020;126:46–57. doi: 10.1002/cncr.32498. PubMed DOI

Cancer Research UK, https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Two, Accessed on April 27th 2020.

European Cancer Information System, https://ecis.jrc.ec.europa.eu/explorer.php, Accessed on April 27th 2020.

Duarte AA, Mohsin S, Golubnitschaja O. Diabetes care in figures: current pitfalls and future scenario. EPMA J. 2018;9:125–131. doi: 10.1007/s13167-018-0133-y. PubMed DOI PMC

Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M, Costigliola V, Grech G. Breast cancer epidemic in the early 21st century: Evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biol. 2016;37:12941–12957. doi: 10.1007/s13277-016-5168-x. PubMed DOI

Polivka J Jr, Altun I, Golubnitschaja O. Pregnancy Associated Breast Cancer: The Risky Status Quo and New Concepts of Predictive Medicine. EPMA J. 2018. 10.1007/s13167-018-0129-7. PubMed PMC

Golubnitschaja O (Ed.). Flammer Syndrome – From Phenotype to Associated Pathologies, Prediction, Prevention and Personalisation V.11, 2019, ISBN 978-3-030-13549-2 ISBN 978-3-030-13550-8 (eBook), 10.1007/978-3-030-13550-8.

Xu Y, Huang D, Wu Y, Ye D, Zhang N, Gao Y, et al. Family history is significantly associated with prostate cancer and its early onset in Chinese population. Prostate. 2019. 10.1002/pros.23900. PubMed

Wilson KM, Mucci LA. Diet and Lifestyle in Prostate Cancer. Adv Exp Med Biol. 2019. 10.1007/978-3-030-32656-2_1. PubMed

Reeves FA, Corcoran NM. Advances in prostate cancer. Aust J Gen Pract. 2020. 10.31128/AJGP-09-19-5055. PubMed

Sharma R. The burden of prostate cancer is associated with human development index: evidence from 87 countries, 1990-2016. EPMA J. 10:2019–152. 10.1007/s13167-019-00169-y. PubMed PMC

Thalgott M, Kron M, Brath JM, Ankerst DP, Thompson IM, Gschwend JE, et al. Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy. World J Urol. 2018. 10.1007/s00345-017-2122-5. PubMed

Russo JW, Balk SP. Initiation and Evolution of Early Onset Prostate Cancer. Cancer Cell. 2018. 10.1016/j.ccell.2018.11.010. PubMed

Tortajada JF, Castell JG, Tornero OB, Garcia JAO. Constitutional risk factors in prostate cancer. Acta Urol Esp. 2011. 10.1016/j.acuro.2010.12.009 Factores de riesgo constitucionales en el cáncer de próstata. PubMed

Zhou CK, Young D, Yeboah ED, Coburn SB, Tettey Y, Biritwum RB, Adjei AA, Tay E, Niwa S, Truelove A, Welsh J, Mensah JE, Hoover RN, Sesterhenn IA, Hsing AW, Srivastava S, Cook MB. TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences. Am J Epidemiol. 2017;186:1352–1361. doi: 10.1093/aje/kwx235. PubMed DOI PMC

Stone L. The IMPACT of BRCA2 in prostate cancer. Nat Rev Urol. 2019;16:639. doi: 10.1038/s41585-019-0249-4. PubMed DOI

Godley PA, Schenck AP, Amamoo MA, Schoenbach VJ, Peacock S, Manning M, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003;95:1702–1710. doi: 10.1093/jnci/djg094. PubMed DOI

Figiel S, Pinault M, Domingo I, Guimaraes C, Guibon R, Besson P, Tavernier E, Blanchet P, Multigner L, Bruyère F, Haillot O, Mathieu R, Vincendeau S, Rioux-Leclercq N, Lebdai S, Azzouzi AR, Perrouin-Verbe MA, Fournier G, Doucet L, Rigaud J, Renaudin K, Mahéo K, Fromont G. Fatty acid profile in peri-prostatic adipose tissue and prostate cancer aggressiveness in African-Caribbean and Caucasian patients. Eur J Cancer. 2018;91:107–115. doi: 10.1016/j.ejca.2017.12.017. PubMed DOI

Wu I, Modlin CS. Disparities in prostate cancer in African-American men: what primary care physicians can do. Cleveland Clin J Med. 2012;79:313–320. doi: 10.3949/ccjm.79a.11001. PubMed DOI

Yedjou CG, Mbemi AT, Noubissi F, Tchounwou SS, Tsabang N, Payton M, et al. Prostate Cancer Disparity, Chemoprevention, and Treatment by Specific Medicinal Plants. Nutrients. 2019. 10.3390/nu11020336. PubMed PMC

Jeong IG, Dajani D, Verghese M, Hwang J, Cho YM, Hong JH, Kim CS, Ahn H, Ro JY. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy. Urol Oncol. 2016;34:3.e9–3.e14. doi: 10.1016/j.urolonc.2015.08.004. PubMed DOI

Akaza H, Kanetake H, Tsukamoto T, Miyanaga N, Sakai H, Masumori N, Nakatsu H, Sagiyama K, Sakamoto S, Endo Y, Yamanouchi T, on behalf of the REDUCE Study Group Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study. Jpn J Clin Oncol. 2011;41:417–423. doi: 10.1093/jjco/hyq221. PubMed DOI

SVOD Web Portal, https://www.svod.cz/analyse.php?modul = vek#, Accessed on April 27th, 2020.

Thompson DJ, Genovese G, Halvardson J, Ulirsch JC, Wright DJ, Terao C, et al. Genetic predisposition to mosaic Y chromosome loss in blood. Nature. 2019. 10.1038/s41586-019-1765-3. PubMed PMC

Gao T, Joyce BT, Liu L, Zheng Y, Dai Q, Zhang Z, Zhang W, Shrubsole MJ, Tao MH, Schwartz J, Baccarelli A, Hou L. DNA methylation of oxidative stress genes and cancer risk in the Normative Aging Study. Am J Cancer Res. 2016;6:553–561. PubMed PMC

Sellami M, Gasmi M, Denham J, Hayes LD, Stratton D, Padulo J, et al. Effects of Acute and Chronic Exercise on Immunological Parameters in the Elderly Aged: Can Physical Activity Counteract the Effects of Aging? Front Immunol. 2018. 10.3389/fimmu.2018.02187. PubMed PMC

Taverna G, Seveso M, Giusti G, Hurle R, Graziotti P, Stifter S, et al. Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer. Curr Gerontol Geriatr Res. 2014. 10.1155/2014/478126. PubMed PMC

Le V, He Y, Aldahl J, Hooker E, Yu EJ, Olson A, et al. Loss of androgen signaling in mesenchymal sonic hedgehog responsive cells diminishes prostate development, growth, and regeneration. PLoS Genet. 2020. 10.1371/journal.pgen.1008588. PubMed PMC

Santos SAA, Camargo AC, Constantino FB, Colombelli KT, Mani F, Rinaldi JC, et al. Maternal Low-Protein Diet Impairs Prostate Growth in Young Rat Offspring and Induces Prostate Carcinogenesis With Aging. J Gerontol A Biol Sci Med Sci. 2019. 10.1093/gerona/gly118. PubMed

Alabed Alibrahim E, Legeay S, Billat PA, Bichon E, Guiffard I, Antignac JP, et al. In vivo comparison of the proangiogenic properties of chlordecone and three of its dechlorinated derivatives formed by in situ chemical reduction. Environ Sci Pollut Res Int. 2019. 10.1007/s11356-019-04353-5. PubMed

Tse LA, Lee PMY, Ho WM, Lam AT, Lee MK, Ng SSM, et al. Bisphenol A and other environmental risk factors for prostate cancer in Hong Kong. Environ Int. 2017. 10.1016/j.envint.2017.06.012. PubMed

Lam HM, Ho SM, Chen J, Medvedovic M, Tam NN. Bisphenol A Disrupts HNF4α-Regulated Gene Networks Linking to Prostate Preneoplasia and Immune Disruption in Noble Rats. Endocrinology. 2016;157:207–219. doi: 10.1210/en.2015-1363. PubMed DOI PMC

Pardo LA, Beane Freeman LE, Lerro CC, Andreotti G, Hofmann JN, Parks CG, et al. Pesticide exposure and risk of aggressive prostate cancer among private pesticide applicators. Environ Health. 2020. 10.1186/s12940-020-00583-0. PubMed PMC

Mezynska M, Brzóska MM. Environmental exposure to cadmium-a risk for health of the general population in industrialized countries and preventive strategies. Environ Sci Pollut Res Int. 2018. 10.1007/s11356-017-0827-z. PubMed

Lim JT, Tan YQ, Valeri L, Lee J, Geok PP, Chia SE, et al. Association between serum heavy metals and prostate cancer risk - A multiple metal analysis. Environ Int. 2019. 10.1016/j.envint.2019.105109. PubMed

Petersen KU, Pedersen JE, Bonde JP, Ebbehøj NE, Hansen J. Mortality in a cohort of Danish firefighters; 1970-2014. Int Arch Occup Environ Health. 91:2018–766. 10.1007/s00420-018-1323-6. PubMed

Zarkovic N. Roles and Functions of ROS and RNS in Cellular Physiology and Pathology. Cells. 2020;9. 10.3390/cells9030767. PubMed PMC

Shukla S, Srivastava JK, Shankar E, Kanwal R, Nawab A, Sharma H, et al. Oxidative Stress and Antioxidant Status in High-Risk Prostate Cancer Subjects. Diagnostics (Basel). 2020. 10.3390/diagnostics10030126. PubMed PMC

Udensi UK, Tchounwou PB. Oxidative stress in prostate hyperplasia and carcinogenesis. J Exp Clin Cancer Res. 2016;35:139. doi: 10.1186/s13046-016-0418-8. PubMed DOI PMC

Soni Y, Softness K, Arora H, Ramasamy R. The Yin Yang Role of Nitric Oxide in Prostate Cancer. Am J Mens Health. 2020;14:155798832090319. doi: 10.1177/1557988320903191. PubMed DOI PMC

Darcey E, Boyle T. Tobacco smoking and survival after a prostate cancer diagnosis: A systematic review and meta-analysis. Cancer Treat Rev. 2018;70:30–40. doi: 10.1016/j.ctrv.2018.07.001. PubMed DOI

Li J, Thompson T, Joseph AD, Master VA. Association between smoking status, and free, total and percent free prostate specific antigen. J Urol. 2012;187:1228–1233. doi: 10.1016/j.juro.2011.11.086. PubMed DOI PMC

Kelly SP, Lennon H, Sperrin M, Matthews C, Freedman ND, Albanes D, Leitzmann MF, Renehan AG, Cook MB. Body mass index trajectories across adulthood and smoking in relation to prostate cancer risks: the NIH-AARP Diet and Health Study. Int J Epidemiol. 2019;48:464–473. doi: 10.1093/ije/dyy219. PubMed DOI PMC

Huncharek M, Haddock S, Reid R, Kupelnick B. Smoking as a risk factor for prostate cancer: A metaanalysis of 24 prospective cohort studies. Am J Public Health. 2010;100:693–701. doi: 10.2105/AJPH.2008.150508. PubMed DOI PMC

Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010. 10.1200/JCO.2009.27.3003. PubMed

Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011;305:2548–2555. doi: 10.1001/jama.2011.879. PubMed DOI PMC

Chung WS, Lin CL. Sleep disorders associated with risk of prostate cancer. A population-based cohort study. BMC Cancer. 2019. 10.1186/s12885-019-5361-6. PubMed PMC

Hoyt MA, Bower JE, Irwin MR, Weierich MR, Stanton AL. Sleep quality and depressive symptoms after prostate cancer: The mechanistic role of cortisol. Behav Neurosci. 2016;130:351–356. doi: 10.1037/bne0000107. PubMed DOI PMC

Maguire R, Drummond FJ, Hanly P, Gavin A, Sharp L. Problems sleeping with prostate cancer: exploring possible risk factors for sleep disturbance in a population-based sample of survivors. Support Care Cancer. 2019;27:3365–3373. doi: 10.1007/s00520-018-4633-z. PubMed DOI

Dimitropoulou P, Lophatananon A, Easton D, Pocock R, Dearnaley DP, Guy M, et al. Sexual activity and prostate cancer risk in men diagnosed at a younger age. BJU Int. 2009. 10.1111/j.1464-410X.2008.08030.x. PubMed

Moustafa AE. Involvement of human papillomavirus infections in prostate cancer progression. Med Hypotheses. 2008;71:209–211. doi: 10.1016/j.mehy.2008.03.036. PubMed DOI

Taylor ML, Mainous AG, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med. 2013;37:506–512. PubMed

Stark JR, Judson G, Alderete JF, et al. Prospective study of Trichomonas vaginalis infection and prostate cancer Incidence and mortality: physicians’ healths. Study J Natl Cancer Inst. 2009;101:1–6. PubMed PMC

Blundon MA, Dasgupta S. Metabolic Dysregulation Controls Endocrine Therapy-Resistant Cancer Recurrence and Metastasis. Endocrinology. 2019. 10.1210/en.2019-00097. PubMed PMC

Izumi K, Shigehara K, Nohara T, Narimoto K, Kadono Y, Mizokami A. Both High and Low Serum Total Testosterone Levels Indicate Poor Prognosis in Patients with Prostate Cancer. Anticancer Res. 2017;37:5559–5564. PubMed

Li L, Yu H, Schumacher F, Casey G, Witte JS. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States) Cancer Causes Control. 2008;14:721–726. doi: 10.1023/A:1026383824791. PubMed DOI

Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011;29:726–732. doi: 10.1200/JCO.2010.31.5226. PubMed DOI PMC

Fabre B, Grosman H, Gonzalez D, Machulsky NF, Repetto EM, Mesch V, Lopez MA, Mazza O, Berg G. Prostate Cancer, High Cortisol Levels and Complex Hormonal Interaction. Asian Pac J Cancer Prev. 2016;17:3167–3171. PubMed

Di Sebastiano KM, Pinthus JH, Duivenvoorden WCM, Mourtzakis M. Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise. Obes Rev. 2018;19:1008–1016. doi: 10.1111/obr.12674. PubMed DOI

Holt SK, Salinas CA, Stanford JL. Vasectomy and the risk of prostate cancer. J Urol. 2008;180:2565–2568. doi: 10.1016/j.juro.2008.08.042. PubMed DOI PMC

Schwing PJ, Meirik O, Kapp N. Farley. Prostate cancer and vasectomy: a hospital-based case-control study in China, Nepal and the Republic of Korea. Contraception. 2009;79:363–368. doi: 10.1016/j.contraception.2008.11.015. PubMed DOI

Huang CH, Chou YH, Yeh HW, Huang JY, Yang SF, Yeh CB. Risk of Cancer after Lower Urinary Tract Infection: A Population-Based Cohort Study. Int J Environ Res Public Health. 2019;16. 10.3390/ijerph16030390. PubMed PMC

Fan CY, Huang WY, Lin KT, Lin CS, Chao HL, Yang JF, et al. Lower Urinary Tract Infection and Subsequent Risk of Prostate Cancer: A Nationwide Population-Based Cohort Study. PLoS One. 2017. 10.1371/journal.pone.0168254. PubMed PMC

Santos PB, Patel H, Henrique R, Félix A. Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer? World J Clin Oncol. 2020. 10.5306/wjco.v11.i2.43. PubMed PMC

Dominguez GA, Polo AT, Roop J, Campisi AJ, Somer RA, Perzin AD, et al. Detecting Prostate Cancer Using Pattern Recognition Neural Networks With Flow Cytometry-Based Immunophenotyping in At-Risk Men. Biomark Insights. 2020. 10.1177/1177271920913320. PubMed PMC

Pinto FG, Mahmud I, Harmon TA, Rubio VY, Garrett TJ. Rapid Prostate Cancer Noninvasive Biomarker Screening Using Segmented Flow Mass Spectrometry-Based Untargeted Metabolomics. J Proteome Res. 2020. 10.1021/acs.jproteome.0c00006. PubMed

Sanguedolce F, Falagario UG, Castellan P, Di Nauta M, Silecchia G, Bruno SM, et al. Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer. Urol Oncol. 2020. 10.1016/j.urolonc.2020.02.025. PubMed

Almeer RS, Muhammad NAE, Othman MS, Aref AM, Elgamal B, Moneim AEA. The Potential Protective Effect of Orange Peel and Selenium against 17β-Estradiol-Induced Chronic Non-Bacterial Prostatitis in Rats. Anticancer Agents Med Chem. 2020;20. 10.2174/1871520620666200331102609. PubMed

Stikbakke E, Richardsen E, Knutsen T, Wilsgaard T, Giovannucci EL, McTiernanA, et al. Inflammatory serum markers and risk and severity of prostate cancer: The PROCA-life study. Int J Cancer. 2019. 10.1002/ijc.32718. PubMed

Gómez-Gómez E, Carrasco-Valiente J, Campos-Hernández JP, Blanca-Pedregosa AM, Jiménez-Vacas JM, Ruiz-García J, et al. Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer. J Cell Mol Med. 2019. 10.1111/jcmm.13994. PubMed PMC

Gacci M, Russo GI, De Nunzio C, Sebastianelli A, Salvi M, Vignozzi L, et al. Meta-analysis of metabolic syndrome and prostate cancer. Prostate Cancer Prostatic Dis. 2017. 10.1038/pcan.2017.1. PubMed

Dickerman BA, Torfadottir JE, Valdimarsdottir UA, Wilson KM, Steingrimsdottir L, Aspelund T, et al. Midlife metabolic factors and prostate cancer risk in later life. Int J Cancer. 2018. 10.1002/ijc.31142. PubMed PMC

Hammarsten J, Damber JE, Haghsheno MA, Mellström D, Peeker R. A stage-dependent link between metabolic syndrome components and incident prostate cancer. Nat Rev Urol. 2018. 10.1038/nrurol.2018.8. PubMed

Lin HW, Lin LF, Chen HC, Liou TH, Huang SW. Chronic obstructive pulmonary disease with short-acting inhaled pharmacotherapy increases the risk of prostate cancer: A two-stage database approach. PLoS One. 2018;13:e0203377. doi: 10.1371/journal.pone.0203377. PubMed DOI PMC

Ozge C, Bozlu M, Ozgur ES, Tek M, Tunckiran A, Muslu N, et al. The impact of hypoxemia on serum total and free prostate-specific antigen levels in patients with chronic obstructive pulmonary disease. Med Oncol. 2015. 10.1007/s12032-015-0602-2. PubMed

Gerner C, Costigliola V, Golubnitschaja O. Multiomic patterns in body fluids: Technological Challenge with a Great Potential to Implement the Advanced Paradigm of 3P Medicine. Mass Spectrometry Reviews. 2019. 10.1002/mas. PubMed

Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6:944–953. doi: 10.1016/S2213-8587(18)30288-2. PubMed DOI PMC

Cao Y, Giovannucci E. Obesity and Prostate Cancer. Recent Results Cancer Res. 2016;208:137–153. doi: 10.1007/978-3-319-42542-9_8. PubMed DOI

Parekh N, Lin Y, Dipaola RS, Marcella S, Yao GL. Obesity and PCa detection: insights from three national surveys. Am J Med. 2010;123:829–835. doi: 10.1016/j.amjmed.2010.05.011. PubMed DOI PMC

Michael J, Oyekunle T, Howard L, De Hoedt A, Hoyo C, Grant D, et al. Interplay between exercise and BMI; results from an equal access, racially diverse biopsy study. Cancer Causes Control. 2019;30:13–20. doi: 10.1007/s10552-018-1104-2. PubMed DOI

Freedland SJ, Wen J, Wuerstle M, Shah A, Lai D, Moalej B, et al. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology. 2012;72:1102–5. PubMed PMC

Cantarutti A, Bonn SE, Adami HO, Grönberg H, Bellocco R, Bälter K. Body mass index and mortality in men with prostate cancer. Prostate. 2015. 10.1002/pros.23001. PubMed

Greenlee H, Unger JM, LeBlanc M, Ramsey S, Hershman DL. Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. Cancer Epidemiol Biomarkers Prev. 2017;26:21–29. doi: 10.1158/1055-9965.EPI-15-1336. PubMed DOI PMC

Zhao J, Stockwell T, et al. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. BMC Cancer. 2016. 10.1186/s12885-016-2891-z. PubMed PMC

Rota M, Scotti L, Turati F, Tramacere I, Islami F, Bellocco R, Negri E, Corrao G, Boffetta P, la Vecchia C, Bagnardi V. Alcohol consumption and prostate cancer risk: a meta-analysis of the dose-risk relation. Eur J Cancer Prev. 2012;21:350–359. doi: 10.1097/CEJ.0b013e32834dbc11. PubMed DOI

Rohrmann S, Linseisen J, Key TJ, Jensen MK, Overvad K, Johnsen NF, et al. Alcohol consumption and the risk for prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2008. 10.1158/1055-9965.EPI-07-2888. PubMed

Downer MK, Kenfield SA, Stampfer MJ, Wilson KM, Dickerman BA, Giovannucci EL. Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study. J Clin Oncol. 2019. 10.1200/JCO.18.02462. PubMed PMC

Gibson TM, Ferrucci LM, Tangrea JA, Schatzkina A. Epidemiological and clinical studies of nutrition. Seminars Oncol. 2010;37:282–296. doi: 10.1053/j.seminoncol.2010.05.011. PubMed DOI PMC

Liss MA, Al-Bayati O, Gelfond J, Goros M, Ullevig S, DiGiovanni J, et al. Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study. Prostate Cancer Prostatic Dis. 2019. 10.1038/s41391-018-0105-2. PubMed PMC

Aune D, Navarro Rosenblatt DA, Chan DS, Vieira AR, Vieira R, Greenwood DC, et al. T. Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies. Am J Clin Nutr. 2015. 10.3945/ajcn.113.067157. PubMed

Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM. Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival. Cancer Prev Res (Phila) 2011;4:2110–2121. doi: 10.1158/1940-6207.CAPR-11-0354. PubMed DOI PMC

Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Zeisel SH, Willett WC, Chan JM. Choline intake and risk of lethal prostate cancer: incidence and survival. Am J Clin Nutr. 2012;96:855–863. doi: 10.3945/ajcn.112.039784. PubMed DOI PMC

Richman EL, Stampfer MJ, Paciorek A, Broering JM, Carroll PR, Chan JM. Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. Am J Clin Nutr. 2010;91:712–721. doi: 10.3945/ajcn.2009.28474. PubMed DOI PMC

Zec S, Minto C, Agostoni C, Fano C, Ocagli H, Lorenzoni G, et al. Communicating Risk Regarding Food Consumption: The Case of Processed Meat. Nutrients. 2019. 10.3390/nu11020400. PubMed PMC

Sinha R, Park Y, Graubard BI, Leitzmann MF, Hollenbeck A, Schatzkin A, Cross AJ. Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States. Am J Epidemiol. 2009;170:1165–1177. doi: 10.1093/aje/kwp280. PubMed DOI PMC

Alexander DD, Mink PJ, Cushing CA, Sceurman B. A review and meta-analysis of prospective studies of red and processed meat intake and prostate cancer. Nutr J. 2010;9:50. doi: 10.1186/1475-2891-9-50. PubMed DOI PMC

Koorts H, Timperio A, Arundell L, Parker K, Abbott G, Salmon J. Is sport enough? Contribution of sport to overall moderate- to vigorous-intensity physical activity among adolescents. J Sci Med Sport. 2019;22:1119–1124. doi: 10.1016/j.jsams.2019.06.009. PubMed DOI PMC

Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2013;105:1132–1141. doi: 10.1093/jnci/djt174. PubMed DOI PMC

Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res. 2011;71:3889–3895. doi: 10.1158/0008-5472.CAN-10-3932. PubMed DOI PMC

Bonn SE, Sjölander A, Lagerros YT, Wiklund F, Stattin P, Holmberg E, et al. Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomarkers Prev. 2015. 10.1158/1055-9965.EPI-14-0707. PubMed

Capece M, Creta M, Calogero A, La Rocca R, Napolitano L, Barone B, et al. Does Physical Activity Regulate Prostate Carcinogenesis and Prostate Cancer Outcomes? A Narrative Review. Int J Environ Res Public Health. 2020;17. 10.3390/ijerph17041441. PubMed PMC

Szymanski KM, Wheeler DC, Mucci LA. Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr. 2010;92:1223–1233. doi: 10.3945/ajcn.2010.29530. PubMed DOI

Koklesova L, Liskova A, Samec M, Qaradakhi T, Zulli A, Smejkal K, Kajo K, Jakubikova J, Behzadi P, Pec M, Zubor P, Biringer K, Kwon TK, Büsselberg D, Sarria GR, Giordano FA, Golubnistschaja O, Kubatka P. Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in context of 3P medicine. EPMA J. 2020;11:261–287. 10.1007/s13167-020-00210-5. PubMed PMC

Galet C, Gollapudi K, Stepanian S, Byrd JB, Henning SM, Grogan T, et al. Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy. Cancer Prev Res (Phila). 2014. 10.1158/1940-6207.CAPR-13-0261. PubMed PMC

Chan JM, Holick CN, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Giovannucci EL. Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States) Cancer Causes Control. 2006;17:199–208. doi: 10.1007/s10552-005-0413-4. PubMed DOI

Grainger EM, Moran NE, Francis DM, Schwartz SJ, Wan L, Thomas-Ahner J, et al. A Novel Tomato-Soy Juice Induces a Dose-Response Increase in Urinary and Plasma Phytochemical Biomarkers in Men with Prostate Cancer. J Nutr. 2019. 10.1093/jn/nxy232. PubMed PMC

Zhang L, Li L, Jiao M, Wu D, Wu K, Li X, Zhu G, Yang L, Wang X, Hsieh JT, He D. Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog–Gli1 pathway. Cancer Lett. 2012;323:48–57. doi: 10.1016/j.canlet.2012.03.037. PubMed DOI

Hsu A, Bruno RS, Löhr CV, Taylor AW, Dashwood RH, Bray TM, et al. Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFκB pathway in the Noble rat model. J Nutr Biochem. 2011. 10.1016/j.jnutbio.2010.04.006. PubMed PMC

Richman EL, Carroll PR, Chan JM. Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer. 2012;131:201–210. doi: 10.1002/ijc.26348. PubMed DOI PMC

Livingstone TL, Beasy G, Mills RD, Plumb J, Needs PW, Mithen R, et al. Plant Bioactives and the Prevention of Prostate Cancer: Evidence from Human Studies. Nutrients. 2019;11. 10.3390/nu11092245. PubMed PMC

Bosland MC, Kato I, Zeleniuch-Jacquotte A, Schmoll J, Enk Rueter E, Melamed J, Kong MX, Macias V, Kajdacsy-Balla A, Lumey LH, Xie H, Gao W, Walden P, Lepor H, Taneja SS, Randolph C, Schlicht MJ, Meserve-Watanabe H, Deaton RJ, Davies JA. Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial. JAMA. 2013;310:170–178. doi: 10.1001/jama.2013.7842. PubMed DOI PMC

Chen P, Zhang W, Wang X, Zhao K, Negi DS, Zhuo L, Qi M, Wang X, Zhang X. Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015;94:e1260. doi: 10.1097/MD.0000000000001260. PubMed DOI PMC

Rowles JL, 3rd, Ranard KM, Applegate CC, Jeon S, An R, Erdman JW., Jr Processed and raw tomato consumption and risk of prostate cancer: a systematic review and dose-response meta-analysis. Prostate Cancer Prostatic Dis. 2018;21:319–336. doi: 10.1038/s41391-017-0005-x. PubMed DOI

Rowles JL, 3rd, Ranard KM, Smith JW, An R, Erdman JW., Jr Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017;20:361–377. doi: 10.1038/pcan.2017.25. PubMed DOI

Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, et al. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr. 2016. 10.3945/ajcn.115.118703. PubMed PMC

Tortajadaa JF, Tornerob OB, Castello JG, Garcíad JAO, Andreue AL. Dietetic factors associated with prostate cancer: protective effects of Mediterranean diet. Actas Urol Esp. 2012;36:239–245. doi: 10.1016/j.acuro.2011.08.002. PubMed DOI

Kumar A, D'silva M, Dholakia K, Levenson AS. In Vitro Anticancer Properties of Table Grape Powder Extract (GPE) in Prostate Cancer. Nutrients. 2018;10. 10.3390/nu10111804. PubMed PMC

Butt NA, Kumar A, Dhar S, Rimando AM, Akhtar I, Hancock JC, Lage JM, Pound CR, Lewin JR, Gomez CR, Levenson AS. Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression. Cancer Med. 2017;6:2673–2685. doi: 10.1002/cam4.1209. PubMed DOI PMC

Deng Y, Li Y, Yang F, Zeng A, Yang S, Luo Y, Zhang Y, Xie Y, Ye T, Xia Y, Yin W. The extract from Punica granatum (pomegranate) peel induces apoptosis and impairs metastasis in prostate cancer cells. Biomed Pharmacother. 2017;93:976–984. doi: 10.1016/j.biopha.2017.07.008. PubMed DOI

Ceci C, Lacal PM, Tentori L, De Martino MG, Miano R, Graziani G. Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. Nutrients. 2018. 10.3390/nu10111756. PubMed PMC

Vyas AR, Moura MB, Hahm ER, Singh KB, Singh SV. Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits. J Cell Biochem. 2016. 10.1002/jcb.25541. PubMed PMC

Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, Hayes RB, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst. 2007;99:1200–1209. doi: 10.1093/jnci/djm065. PubMed DOI

Tummala R, Lou W, Gao AC, Nadiminty N. Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells. Mol Cancer Ther. 2017;16:2770–2779. doi: 10.1158/1535-7163.MCT-17-0030. PubMed DOI PMC

Yang F, Song L, Wang H, Wang J, Xu Z, Xing N. Quercetin in prostate cancer: Chemotherapeutic and chemopreventive effects, mechanisms and clinical application potential (Review) Oncol Rep. 2015;33:2659–2668. doi: 10.3892/or.2015.3886. PubMed DOI

Zhao J, Liu J, Wei T, Ma X, Cheng Q, Huo S, et al. Quercetin-loaded nanomicelles to circumvent human castration-resistant prostate cancer in vitro and in vivo. Nanoscale. 2016. 10.1039/c5nr08966b. PubMed

Beynon RA, Richmond RC, Santos Ferreira DL, Ness AR, May M, Smith GD, Vincent EE, Adams C, Ala-Korpela M, Würtz P, Soidinsalo S, Metcalfe C, Donovan JL, Lane AJ, Martin RM, the ProtecT Study Group. The PRACTICAL consortium Investigating the effects of lycopene and green tea on the metabolome of men at risk of prostate cancer: The ProDiet randomised controlled trial. Int J Cancer. 2019;144:1918–1928. doi: 10.1002/ijc.31929. PubMed DOI PMC

Ying L, Yan F, Williams BR, Xu P, Li X, Zhao Y, et al. (-)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells. Clin Exp Pharmacol Physiol. 2018. 10.1111/1440-1681.12854. PubMed

Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J. 2011;25:1198–1207. doi: 10.1096/fj.10-167924. PubMed DOI PMC

Geybels MS, Neuhouser ML, Wright JL, Stott-Miller M, Stanford JL. Coffee and tea consumption in relation to prostate cancer prognosis. Cancer Causes Control. 2013;24:1947–1954. doi: 10.1007/s10552-013-0270-5. PubMed DOI PMC

Wilson KM, Kasperzyk JL, Rider JR, Kenfield S, van Dam RM, Stampfer MJ, Giovannucci E, Mucci LA. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst. 2011;103:876–884. doi: 10.1093/jnci/djr151. PubMed DOI PMC

Discacciati A, Orsini N, Wolk A. Coffee consumption and risk of nonaggressive, aggressive and fatal prostate cancer-a dose-response meta-analysis. Ann Oncol. 2014;25:584–591. doi: 10.1093/annonc/mdt420. PubMed DOI PMC

Kovács T, Mikó E, Ujlaki G, Sári Z, Bai P. The Microbiome as a Component of the Tumor Microenvironment. Adv Exp Med Biol. 2020. 10.1007/978-3-030-35727-6_10. PubMed

Matsushita M, Fujita K, Nonomura N. Influence of Diet and Nutrition on Prostate Cancer. Int J Mol Sci. 2020;21. 10.3390/ijms21041447. PubMed PMC

Bubnov R, Babenko L, Lazarenko L, Kryvtsova M, Shcherbakov O, Zholobak N, et al. Can tailored nanoceria act as a prebiotic? Report on improved lipid profile and gut microbiota in obese mice. EPMA J. 2019;10:317–335. doi: 10.1007/s13167-019-00190-1. PubMed DOI PMC

Thomas LV, Suzuki K, Zhao J. Probiotics: a proactive approach to health. A symposium report. Br J Nutr. 2015;114:S1–S15. doi: 10.1017/S0007114515004043. PubMed DOI

Essén A, Santaolalla A, Garmo H, Hammar N, Walldius G, Jungner I, Malmström H, Holmberg L, van Hemelrijck M. Baseline serum folate, vitamin B12 and the risk of prostate and breast cancer using data from the Swedish AMORIS cohort. Cancer Causes Control. 2019;30:603–615. doi: 10.1007/s10552-019-01170-6. PubMed DOI

Zheng Z, Luo G, Shi X, Long Y, Shen W, Li Z, et al. The Xc- inhibitor sulfasalazine improves the anti-cancer effect of pharmacological vitamin C in prostate cancer cells via a glutathione-dependent mechanism. Cell Oncol (Dordr). 2020. 10.1007/s13402-019-00474-8. PubMed

Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019. 10.1056/NEJMoa1809944. PubMed PMC

Barnett CM, Beer TM. Prostate cancer and vitamin D: what does the evidence really suggest? Urol Clin North Am. 2011. 10.1016/j.ucl.2011.04.007. PubMed

Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, Nimptsch K, Hollis BW, DuPre N, Platz EA, Stampfer MJ, Giovannucci E. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012;104:690–699. doi: 10.1093/jnci/djs189. PubMed DOI PMC

Schöttker B, Ball D, Gellert C, Brenner H. Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev. 2013. 10.1016/j.arr.2012.02.004. PubMed

Petrou S, Mamais I, Lavranos G, Tzanetakou IP, Chrysostomou S. Effect of Vitamin D Supplementation in Prostate Cancer: A Systematic Review of Randomized Control Trials. Int J Vitam Nutr Res. 2018. 10.1024/0300-9831/a000494. PubMed

Yang CS, Li G, Yang Z, Guan F, Chen A, Ju J. Cancer prevention by tocopherols and tea polyphenols. Cancer Lett. 2013. 10.1016/j.canlet.2013.01.051. PubMed PMC

Yang CS, Suh N, Kong AN. Does vitamin E prevent or promote cancer? Cancer Prev Res (Phila). 2012. 10.1158/1940-6207.CAPR-12-0045. PubMed PMC

Ju J, Picinich SC, Yang Z, Zhao Y, Suh N, Kong AN, Yang CS. Cancer preventive activities of tocopherols and tocotrienols. Carcinogenesis. 2010;31:533–542. doi: 10.1093/carcin/bgp205. PubMed DOI PMC

Hoyt M, Reger M, Marley A, Fan H, Liu Z, Zhang J. Vitamin K intake and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. Am J Clin Nutr. 2019;109:392–401. doi: 10.1093/ajcn/nqy251. PubMed DOI

Hurst R, Hooper L, Norat T, Lau R, Aune D, Greenwood DC, Vieira R, Collings R, Harvey LJ, Sterne JAC, Beynon R, Savović J, Fairweather-Tait SJ. Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr. 2012;96:111–122. doi: 10.3945/ajcn.111.033373. PubMed DOI

Kenfield SA, Van Blarigan EL, DuPre N, Stampfer MJ, Giovannucci EL, Chan JM. Selenium supplementation and prostate cancer mortality. J Natl Cancer Inst. 2014. 10.1093/jnci/dju360. PubMed PMC

Cui J, Yan M, Liu X, Yin S, Lu S, Fan L, Hu H. Inorganic Selenium Induces Nonapoptotic Programmed Cell Death in PC-3 Prostate Cancer Cells Associated with Inhibition of Glycolysis. J Agric Food Chem. 2019;67:10637–10645. doi: 10.1021/acs.jafc.9b03875. PubMed DOI

SVOD Web Portal, https://www.svod.cz/analyse.php?modul = incmor#, Accessed on April 27th, 2020.

SVOD Web Portal, https://www.svod.cz/analyse.php?modul=stadia&diag=C61& zobrazeni = bar&vypocet = p&pohl = m&kraj = &vek_od = 1&vek_do = 18&obdobi_od = 1977&obdobi_do = 2017&zije = &umrti = &lecba=, Accessed on April 27th, 2020.

Kato T, Sugimoto M. Quality of life in active surveillance for early prostate cancer. Int J Urol. 2020;27:296–306. doi: 10.1111/iju.14202. PubMed DOI

Sedlackova H, Dolejsova O, Hora M, Ferda J, Hes O, Topolcan O, et al. Prostate Cancer Diagnostic Algorithms: a “Road Map” from the First Stratification of the Patient to the Final Treatment Decision. EPMA J. 2020. 10.1007/s13167-020-00206-1. PubMed PMC

Dolejsova O, Kucera R, Fuchsova R, Topolcan O, Svobodova H, Hes O, Eret V, Pecen L, Hora M. The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6-A Study on 320 Patients After Radical Prostatectomy. Technol Cancer Res Treat. 2018;17:153303381878737. doi: 10.1177/1533033818787377. PubMed DOI PMC

Hendriks RJ, van Oort IM, Schalken JA. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis. 2017;20:12–19. doi: 10.1038/pcan.2016.59. PubMed DOI

Ferda J, Baxa J, Ferdova E, Kucera R, Topolcan O, Molacek J. Abdominal aortic aneurysm in prostate cancer patients: the "road map" from incidental detection to advanced predictive, preventive, and personalized approach utilizing common follow-up for both pathologies. EPMA J. 2019;10:415–423. doi: 10.1007/s13167-019-00193-y. PubMed DOI PMC

Koerber SA, Will L, Kratochwil C, Haefner MF, Rathke H, Kremer C, et al. (68)Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients. J Nucl Med. 2018. 10.2967/jnumed.118.211086. PubMed PMC

Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol. 2015;68:438–450. doi: 10.1016/j.eururo.2014.11.037. PubMed DOI

Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016. 10.1097/PAS.0000000000000530. PubMed

Gustavsen G, Gullet L, Cole D, Lewine N, Bishoff JT. Economic burden of illness associated with localized prostate cancer in the United States. Future Oncol. 2020. 10.2217/fon-2019-0639. PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 66:2016–30. 10.3322/caac.21332. PubMed

Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 103:2011–128. 10.1093/jnci/djq495. PubMed PMC

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014. 10.1016/j.eururo.2013.12.062. PubMed PMC

Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012. 10.1056/NEJMoa1113162. PubMed PMC

Aizer AA, Gu X, Chen MH, Choueiri TK, Martin NE, Efstathiou JA, Hyatt AS, Graham PL, Trinh QD, Hu JC, Nguyen PL. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw. 2015;13:61–68. doi: 10.6004/jnccn.2015.0009. PubMed DOI

Mahumud RA, Alam K, Dunn J, Gow J. The burden of chronic diseases among Australian cancer patients: Evidence from a longitudinal exploration, 2007-2017. PLoS One. 15:2020. 10.1371/journal.pone.0228744. PubMed PMC

Seifirad S, Haghpanah V. Inappropriate modeling of chronic and complex disorders: How to reconsider the approach in the context of predictive, preventive and personalized medicine, and translational medicine. EPMA J. 2019;10:195–209. doi: 10.1007/s13167-019-00176-z. PubMed DOI PMC

Kelly SP, Anderson WF, Rosenberg PS, Cook MB. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States. Eur Urol Focus. 2018. 10.1016/j.euf.2017.10.014. PubMed PMC

Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation – EPMA position paper 2016. EPMA J. 2016;7. 10.1186/s13167-016-0072-4. PubMed PMC

Golubnitschaja O, Andrews RJ. (2018). Book-chapter “Patient-Centered Care: Making the Modern Hospital Truly Modern”. In the book The Modern Hospital: Patients Centered, Disease Based, Research Oriented, Technology Driven, Ed: Rifat Latifi, Springer, ISBN 978-3-030-01393-6.

Qian S, Golubnitschaja O, Zhan X. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J. 2019;10:365–381. doi: 10.1007/s13167-019-00194-x. PubMed DOI PMC

Mandel PC, Huland H, Tiebel A, Haese A, Salomon G, Budäus L, Tilki D, Chun F, Heinzer H, Graefen M, Pantel K, Riethdorf S, Steuber T. Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial. Eur Urol Focus. 2019;S2405-4569(19):30145–30142. doi: 10.1016/j.euf.2019.05.008. PubMed DOI

Lu M, Zhan X. The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA J. 2018;9:77–102. doi: 10.1007/s13167-018-0128-8. PubMed DOI PMC

Ischemic stroke of unclear aetiology: a case-by-case analysis and call for a multi-professional predictive, preventive and personalised approach

Caution, "normal" BMI: health risks associated with potentially masked individual underweight-EPMA Position Paper 2021

Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles

Prostate Cancer Diagnostic Algorithm as a "Road Map" from the First Stratification of the Patient to the Final Treatment Decision